Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Study acronym: ENLIGHTEN-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-12-05; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07282600
Lead Sponsor Eli Lilly and Company
Conditions Overweight, Obesity
Enrollment 1,035 participants
Start Date 2025-12-15
Primary Completion 2028-01 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06